Analysis of circulating cell-free tumor DNA from lung tumors and diffuse large B-cell lymphomas for early detection and selection of patients for precision medicine

The first step in the therapy of lung and hematological cancers is adequate diagnosis. Analysis of circulating tumor DNA by massively parallel sequencing is a non-invasive approach for early detection without a tissue biopsy. This approach is also promising for the development of a test for selection of cancer patients who could benefit from immunotherapy and precision medicine.